Skip to main content

Table 1 Baseline characteristics of the study population

From: Prognosis after percutaneous coronary intervention in patients with psoriasis: a cohort study using Danish nationwide registries

  No psoriasis Mild psoriasis Severe psoriasis p–value
  n=51,752 n=1074 n=315  
Male (%) 36,989 (71.5) 767 (71.4) 193 (61.3) 0.003
Female (%) 14,763 (28.5) 307 (28.6) 122 (38.7)  
Age, years (SD) 65.1 (11.6) 65.0 (10.7) 63.5 (10.9) 0.06
Treatment (%)     
  Beta-blocker 20,851 (40.3) 434 (40.4) 132 (41.9) 0.60
  ACE inhibitor/ARB 16,868 (32.6) 381 (35.5) 121 (38.4) 0.003
  Statin 21,462 (41.5) 506 (47.1) 136 (43.2) 0.003
  Platelet inhibitor 21,209 (41.0) 490 (45.6) 133 (42.2) 0.02
  Loop diuretic 6663 (12.9) 139 (12.9) 48 (15.2) 0.33
  Spironolactone 1733 (3.4) 38 (3.5) 11 (3.5) 0.74
  Vitamin K antagonist 2505 (4.8) 48 (4.5) 11 (3.5) 0.23
  Glucose lowering medication 5734 (11.1) 123 (11.5) 52 (16.5) 0.01
  NSAID 3465 (6.7) 101 (9.4) 36 (11.4) <0.001
  Antidepressive medication 4569 (8.8) 125 (11.6) 42 (13.3) <0.001
Comorbidity (%)     
  Myocardial infarction 31,078 (60.1) 596 (55.5) 182 (60.0) 0.008
  Cardiac dysrhythmia 4759 (9.2) 115 (10.7) 28 (3.2) 0.33
  Diabetes with complications 2117 (4.1) 38 (3.5) 22 (7.0) 0.20
  Cerebrovascular disease 1373 (2.7) 33 (3.1) 10 (3.2) 0.32
  Pulmonary edema 187 (0.4) 5 (0.5) 2 (0.6) 0.33
  Shock 593 (1.2) 6 (0.6) 8 (2.5) 0.62
  Cancer 424 (0.8) 9 (0.8) 3 (1.0) 0.62
  Acute renal failure 331 (0.6) 2 (0.2) 3 (1.0) 0.46
  Chronic renal failure 592 (1.1) 8 (0.2) 4 (1.1) 0.51
  Chronic renal failure 1904 (3.7) 50 (4.7) 15 (4.8) 0.06
  pulmonary disease     
  1. ACE: angiotensin-converting enzyme inhibitor; ARB: angiotensin 2 receptor blocker; NSAID: Non-steroid anti-inflammatory drug.